| Name | Title | Contact Details |
|---|
Full Swing is the worldwide leader in cutting-edge indoor golf simulation technology. Full Swing simulators are in the homes of top Tour Pros including Tiger Woods, Jordan Spieth, Jason Day, Jim Furyk, Padraig Harrington, Smylie Kaufman, and many more. Our patented dual tracking technology delivers superior ball tracking data and makes Full Swing the only simulator that actually measures ball flight indoors. With over 30 years of experience, Full Swing provides the most accurate and realistic golf experience you can find. From practice to instruction, to entertainment, this is the world-class experience youve been looking for. For further information, please visit www.fullswinggolf.com.
LIV Golf is a global sports league featuring individual and team competition, a 14-tournament schedule, and many of the worlds best golfers. Founded in 2021, LIV Golf League was designed to expand the game on an international level and unlock the sports true economic and societal potential. Greg Norman, Hall of Fame golfer and renowned businessman, is the leagues first and founding CEO and Commissioner. With tournaments across North and Latin Americas, Asia, Australia, the Middle East and Europe, LIV Golf is growing and improving the game for fans and golfers alike. LIV Golf launched in 2022 as an eight-event ‘Invitational Series, while simultaneously backing The International Series as an exciting new addition to the Asian Tour. 2023 saw the inaugural LIV Golf League host 14 events around the world, from Adelaide to Chicago, Andalucía to Singapore, as well as launch the games first Team franchises, captained by some of golfs most decorated superstars. The format, respecting the historic traditions of the game, has been optimized for modern-day sports fans: 3 days, 54 holes, no cut, and a shotgun start - offering an immersive fan experience, with a faster pace of play to drive engaging storylines. In 2024, LIV Golf further expanded the reach of the League, splitting the schedule between some of the most iconic venues across Asia, Europe and the Middle East with decorated venues in the US. The full player pathway, created in partnership with the Asian Tour, also launched, with the games first ever player Promotion and Relegation and Player Transfer Window. Off the course, LIV Golf League is dedicated to enhancing the wellbeing of its communities through its ground-breaking social impact and sustainability strategy. ‘Potential, Unleashed reflects the leagues commitment to giving back and improving the world through golf.
"Love of invention will never end." - Carl Benz Learn more about us as we continue to pioneer the future of driving excellence. Data privacy: mb4.me/provider_privacy Imprint: Mercedes-Benz AG Mercedesstraße 120 D-70372 Stuttgart Deutschland Tel.: +49 7 11 17-0 E-Mail: dialog.mb@mercedes-benz.com Vertreten durch den Vorstand: Ola Källenius (Vorsitzender), Jörg Burzer, Renata Jungo Brüngger, Sabine Kohleisen, Harald Wilhelm, Markus Schäfer, Britta Seeger Vorsitzender des Aufsichtsrats: Martin Brudermüller Handelsregister beim Amtsgericht Stuttgart, Nr. HRB 762873 Umsatzsteueridentifikationsnummer: DE321281763
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.